SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
PRME reported three months ended September 30, 2026 results. The stock moved +9.8% on the print.
PRMEearnings

Earnings reactions, page 3

Prime Medicine, Inc. (PRME) FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Research and Development (R&D) expenses were $34.1 million for the three months ended September 30, 2026.
  • General and Administrative (G&A) expenses were $10.0 million for the three months ended September 30, 2026.
  • Net loss was $39.0 million for the three months ended September 30, 2026.
  • Net loss per share attributable to common stockholders, basic and diluted was $(0.22) for the three months ended September 30, 2026.
  • The company raised $143.7 million in gross proceeds from an underwritten public offering in November 2026.

Guidance

  • Prime Medicine expects that its cash, cash equivalents and investments as of September 30, 2026, together with net proceeds from its follow-on public offering of $134.7 million in November 2026, will be sufficient to fund its operating expenses and capital expenditure requirements through 2027.

Price and volatility reaction

The stock moved +9.8% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release3.892026-11-12
Close after release4.272026-11-13
Realised move+9.8%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →